Active Recombinant Human IL33 Protein (159 aa)

• Cat.No.: IL33-356I
• Product Overview: Recombinant humanInterleukin-33 (rhIL-33) produced in E. coli is a single non-glycosylated polypeptide chain containing 159 amino acids. A fully biologically active molecule, rhIL-33 has a molecular mass of 18.0 kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques.

Specification

• Description: Interleukin-33 (IL-33) is a proinflammatory cytokine that belongs to the IL-1 family. IL-33 is expressed in a variety of cells, including epithelial and endothelial cells, smooth muscle cells, macrophages and fibroblasts. The primary receptors for IL-33 are ST2 and IL-1 receptor accessory protein (IL-1RAcP), both of which belong to the IL-1 receptor family. IL-33 is localized to the nucleus of resting cells where it binds to chromatin in the H2A-H2B histone complex as a transcriptional suppressor. IL-33 is secreted by cells during injury which induces a T-helper 2 type inflammatory response. Evidence suggests IL-33 plays a role in autoimmune disease. IL-33's interaction with ST2 can drive allergic pathology and IL-33 has been reported to play a role in the development of rheumatoid arthritis and systemic lupus erythematosus.
• Source: E. coli
• Species: Human
• Form: Sterile Filtered White lyophilized (freeze-dried) powder.
• Bio-activity: ED50 < 0.5 ng/mL, measured by a cell proliferation assay using D10S cells, corresponding to a specific activity of > 2 × 10^6 units/mg.
• Molecular Mass: 18.0 kDa, observed by reducing SDS-PAGE.
• Protein length: 159
• AA Sequence: SITGISPITEYLASLSTYNDQSITF ALEDESYEIYVEDLKKDEKKDKVLL SYYESQHPSNESGDGVDGKMLMVTL SPTKDFWLHANNKEHSVELHKCEKP LPDQAFFVLHNMHSNCVSFECKTDP GVFIGVKDNHLALIKVDSSENLCTE NILFKLSET
• Endotoxin: < 0.2 EU/μg, determined by LAL method.
• Purity: > 95% by SDS-PAGEanalysis.
• Storage: Lyophilized recombinant human Interleukin-33 (rhIL-33) remains stable up to 6 months at -80 centigrade from date of receipt. Upon reconstitution, rhIL-33 remains stable up to 2 weeks at 4 centigrade or up to 3 months at -20 centigrade.
• Storage Buffer: Lyophilized after extensive dialysis against PBS.
• Reconstitution: Reconstituted in ddH2O at 100 μg/mL.

Gene Information

• Gene Name: IL33 interleukin 33 [ Homo sapiens ]
• Official Symbol: IL33
• Synonyms: IL33; interleukin 33; C9orf26, chromosome 9 open reading frame 26 (NF HEV); interleukin-33; DKFZp586H0523; DVS27; DVS27 related protein; IL1F11; interleukin 1 family; member 11; NF HEV; nuclear factor for high endothelial venules; IL-33; IL-1F11; DVS27-related protein; interleukin-1 family member 11; nuclear factor from high endothelial venules; NF-HEV; NFEHEV; C9orf26; RP11-575C20.2
• Gene ID: 90865
• mRNA Refseq: NM_001199640
• Protein Refseq: NP_001186569
• MIM: 608678
• UniProt ID: O95760

Reviews

10/16/2021

Good solubility and is easy to operate and purify.

05/03/2021

Effectively mimics the function of the target protein in vitro.

03/18/2020

IL33 has a wide range of applications in the field of scientific research and is suitable for a variety of experimental design and research purposes.

Q&As

Which immune cells can recombinant IL33 be used to detect?

It can be used to detect immune cells such as macrophages and dendritic cells.

In what research fields can recombinant IL33 be applied?

This protein applied in immunology, drug research, life science and other fields.

What is the action mechanism of IL33?

Regulates the activity of immune cells by binding to receptors to stimulate the production of inflammatory factors such as interferon and TNF-α.

Besides treating asthma and hay fever, what other diseases can be treated with IL33?

IL33 can also be used to treat a variety of inflammatory diseases, such as inflammatory bowel disease, psoriasis and so on.

How to prepare IL33?

The preparation of IL33 requires first cloning the IL33 gene into the expression vector, and then the expression vector is expressed and purified in the cell culture medium.

How long does it take to treat asthma with IL33?

Treating asthma with recombinant IL33 takes several weeks to several months to be effective, depending on the severity of the condition and the individual patient.